Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation

by Ramasundarahettige, Chinthanie , Avezum, Alvaro , Fana, Golden , Ogah, Okechukwu S. , Chillo, Pilly , Hu, Dayi , Lwabi, Peter , Karthikeyan, Ganesan , Gitura, Bernard , Sharma, Sanjib K. , van Eikels, Martin , Haileamlak, Abraham , Gondwe, Lillian , Benz, Alexander , Paniagua, Maria , Connolly, Stuart J. , Damasceno, Albertino , El Ghamrawy, Alaa , Yusuf, Salim , Kazmi, Khawar , Kamanzi, Emmanuel R. , Balasubramanian, Kumar , Zühlke, Liesl , Pattath, Divya , Gonzalez-Hermosillo, J. Antonio , Dans, Antonio M.L. , Cabral, Tantchou T.J. , Mayosi, Bongani , Ntsekhe, Mpiko , Tarhuni, Wadea M. , Maklady, Fathi , El Sayed, Ahmed , Rangarajan, Sumathy , Musuku, John , Krol, Amy , Ma, Changsheng , Molefe-Baikai, Onkabetse J.

in Allergy / Anticoagulants / Anticoagulants - adverse effects / Anticoagulants - therapeutic use / Anticoagulation / Arrhythmias / Atrial Fibrillation - drug therapy / Atrial Fibrillation - etiology / Autoimmune Disease / Autoimmune diseases / Bacterial Infections / Bleeding / Blood clots / Cardiac arrhythmia / Cardiology / Cardiovascular disease / Cerebral infarction / Clinical trials / Coronary artery disease / Creatinine / Death / Defibrillators / Disease prevention / Echocardiography / Embolism / Embolisms / Factor Xa Inhibitors - adverse effects / Factor Xa Inhibitors - therapeutic use / Female / Fibrillation / Global Health / Heart attacks / Heart diseases / Hemorrhage - chemically induced / Hemostasis / Humans / Immunology / Infectious Disease / Inflammatory Disease / Low income groups / Male / Medical research / Middle Aged / Myocardial infarction / Pacemakers / Rheumatic heart disease / Rheumatic Heart Disease - complications / Rheumatic Heart Disease - diagnosis / Rheumatic Heart Disease - diagnostic imaging / Rheumatology / Rivaroxaban - adverse effects / Rivaroxaban - therapeutic use / Stroke / Stroke - etiology / Stroke - prevention & control / Survival / Thromboembolism / Thrombosis / Treatment Outcome / Valvular Heart Disease / Vitamin K / Vitamin K - antagonists & inhibitors / Warfarin - adverse effects / Warfarin - therapeutic use

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation

2022

Confirm

Do you wish to request the book?

Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation

Ramasundarahettige, Chinthanie,

Avezum, Alvaro,

Fana, Golden,

Ogah, Okechukwu S.,

Chillo, Pilly,

Hu, Dayi,

Lwabi, Peter,

Karthikeyan, Ganesan,

Gitura, Bernard,

Sharma, Sanjib K.,

van Eikels, Martin,

Haileamlak, Abraham,

Gondwe, Lillian,

Benz, Alexander,

Paniagua, Maria,

Connolly, Stuart J.,

Damasceno, Albertino,

El Ghamrawy, Alaa,

Yusuf, Salim,

Kazmi, Khawar,

Kamanzi, Emmanuel R.,

Balasubramanian, Kumar,

Zühlke, Liesl,

Pattath, Divya,

Gonzalez-Hermosillo, J. Antonio,

Dans, Antonio M.L.,

Cabral, Tantchou T.J.,

Mayosi, Bongani,

Ntsekhe, Mpiko,

Tarhuni, Wadea M.,

Maklady, Fathi,

El Sayed, Ahmed,

Rangarajan, Sumathy,

Musuku, John,

Krol, Amy,

Ma, Changsheng,

Molefe-Baikai, Onkabetse J.

2022

Overview

Among patients with rheumatic heart disease and atrial fibrillation who received a vitamin K antagonist or rivaroxaban, the rate of stroke, systemic embolism, MI, or death from vascular or unknown causes was lower with a VKA, without increased bleeding.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Allergy

/ Anticoagulants

/ Anticoagulants - adverse effects

/ Anticoagulants - therapeutic use

/ Anticoagulation

/ Arrhythmias

/ Atrial Fibrillation - drug therapy